enGene Therapeutics (ENGN) Insider Joustra Buys 31,000 Shares
Wouter Joustra added to his holdings in enGene Therapeutics Inc. on June 16, 2026, joining a group of insiders making purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Wouter Joustra bought 31,000 shares of enGene Therapeutics Inc. ($ENGN) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ENGN is down 2.3% after 1 week, up 9.7% after 1 month and down 4.6% to date (from the $1.75 close on Jun 16, 2026).
ENGN
enGene Therapeutics Inc.
Key Points
- Wouter Joustra bought 31,000 shares of enGene Therapeutics Inc. (ENGN) on June 16, 2026.
- Several other insiders, including Interim Chief Medical Officer William Grossman, also acquired shares on the same date.
- enGene Therapeutics trades around $1.74 per share with a hold consensus rating from analysts.
Get $ENGN trade alerts by text
We text you when insiders, Congress or big funds trade $ENGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated enGene Therapeutics Inc. alert may contain errors. Disclosures
Insider Buying and Selling at enGene Therapeutics Inc.
Wouter Joustra added to his stake in enGene Therapeutics Inc. (NasdaqCM: ENGN) by purchasing 31,000 shares on June 16, 2026. This transaction follows a pattern of insider activity recorded on the exact same date for the clinical-stage biotechnology company.
Broad Insider Buying Activity on June 16
The purchase by Joustra aligns with a wave of insider acquisitions processed on June 16, 2026. Other figures associated with the firm also picked up shares that day. Michael Heffernan acquired 31,000 shares, Philip Astley-Sparke bought 31,000 shares, Paul Hastings added 31,000 shares, Lota Zoth picked up 31,000 shares, and Richard Glickman grabbed 31,000 shares. Additionally, Interim Chief Medical Officer William Grossman purchased a larger block of 231,000 shares on the same date.
enGene Therapeutics Stock Trades Near Recent Lows
The company's shares changed hands around $1.74 recently, sitting well below its 52-week high of $12.25 and closer to its 52-week low of $1.40. The stock has a 50-day moving average of $1.83 and a 200-day moving average of $5.36.
Analysts Set New Price Targets
Wall Street firms have recently updated their outlooks on the biotechnology firm. On September 8, 2026, HC Wainwright & Co. reiterated a Buy rating with a $4.00 price target. Soon after, on September 9, 2026, Citizens reiterated a Market Perform rating. Overall, the stock carries a consensus recommendation rating of hold, with a mean price target of $3.29 across 7 analyst opinions.
Developing Genetic Medicines in Canada
enGene Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Montreal, Canada, that develops genetic medicines for bladder cancer patients. Its lead product candidate is detalimogene voraplasmid for non-muscle invasive bladder cancer.
What to Watch Next for ENGN
Investors will look toward the company's next earnings report, scheduled for January 4, 2027, for further updates on its clinical pipeline and financial position. Insider transactions will continue to be tracked via regulatory filings to monitor executive sentiment.
Related Filing Alerts
Source: Wouter Joustra's Form 4 filing on $ENGN (Jun 16, 2026). Find the original filing: ENGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts